A5030249492- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Advanced Radiotherapy Techniques
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Head and Neck Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Gastric Cancer Management and Outcomes
- Hematopoietic Stem Cell Transplantation
- Glioma Diagnosis and Treatment
- Effects and risks of endocrine disrupting chemicals
- Colorectal and Anal Carcinomas
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Acute Myeloid Leukemia Research
- Sarcoma Diagnosis and Treatment
Johns Hopkins University
2016-2025
NRG Oncology
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Air Force Medical University
2022-2025
Chinese PLA General Hospital
2019-2025
Pennsylvania State University
2025
University of Hong Kong
2025
University of Pennsylvania
2025
University of Hong Kong - Shenzhen Hospital
2025
Guangzhou Medical University
2025
Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimensional conformal external beam (3D-CRT) have not been compared prospectively. This study compares 3D-CRT outcomes for NSCLC in a large prospective clinical trial. Patients Methods A secondary analysis was performed compare with NRG Oncology trial RTOG 0617, which patients received concurrent chemotherapy of carboplatin paclitaxel...
PURPOSE RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non–small-cell lung cancer (NSCLC). METHODS The study used a 2 × factorial design dose as 1 factor other, primary end point overall survival (OS). RESULTS Median follow-up was 5.1 years. There were 3 grade 5 adverse events (AEs) in SD arm 9 HD arm. Treatment-related ≥3 dysphagia esophagitis occurred 3.2% 5.0% patients v...
To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer.Patients distal or middle-third, clinical primary tumor stage 3-4 and/or regional lymph node-positive cancer were randomly assigned (1:1) (25 Gy five fractions over 1 week) four cycles (total neoadjuvant therapy [TNT]) (50 25 5 weeks, concurrently capecitabine [chemoradiotherapy; CRT]). Total...
Robert D. Timmerman, MD; Rebecca Paulus, BS; Harvey I. Pass, Elizabeth M. Gore, Martin J. Edelman, James Galvin, DSc; William L. Straube, MS; Lucien A. Nedzi, Ronald C. McGarry, MD, PhD; Cliff G. Robinson, Peter B. Schiff, Garrick Chang, Billy W. Loo Jr, Jeffrey Bradley, Hak Choy, MD
<h3>Importance</h3> The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non–small cell lung cancer (NSCLC). <h3>Objective</h3> To evaluate the effect PORT using modern techniques on survival and safety patients with NSCLC after complete resection adjuvant chemotherapy. <h3>Design, Setting, Participants</h3> PORT-C randomized clinical trial was conducted 394 treated 4 cycles platinum-based chemotherapy between January 2009 December 2017. Data were...
Abstract There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients. Patient‐derived organoid (PDO) has become an important preclinical model. Herein, a living biobank with 50 CRLM organoids derived from primary tumors paired metastatic lesions successfully constructed. PDOs the multiomics levels (histopathology, genome, transcriptome single‐cell sequencing) are comprehensively analyzed confirmed that this...
Abstract Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity dual programmed cell death protein 1 (PD-1) lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab–relatlimab B, in combination chemoradiotherapy 32 patients resectable stage II/stage III...
8506 Background: First line therapy options for advanced NSCLC without actionable molecular alterations include immunotherapy (IO) -/+ chemotherapy or alone. NRG-LU002 was a randomized phase II/III study assessing the benefits of local consolidative (LCT) when added to systemic as maintenance in management oligometastatic NSCLC. Methods: Eligible patients had metastatic with 3 fewer extracranial sites (excluding primary) exhibiting at least stable disease after 4 cycles 1 st therapy....
The rate of erroneous conviction innocent criminal defendants is often described as not merely unknown but unknowable. There no systematic method to determine the accuracy a conviction; if there were, these errors would occur in first place. As result, very few false convictions are ever discovered, and those that discovered representative group whole. In United States, however, high proportion do come light produce exonerations concentrated among tiny minority cases which sentenced death....
A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate the high-dose therapy (RT) arm (74 Gy) than low-dose (60 with concurrent chemotherapy.The primary QOL hypothesis predicted clinically meaningful decline quality of life (QOL) via Functional Assessment Cancer (FACT)-Lung Subscale (LCS) RT at 3 months.The RTOG 0617 was phase study (conducted from November...
Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among
Systemic exposure to nanoparticles induces immune responses that lead anticancer activation.
The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS). effect therapy intensification on cognitive function (CF) remains a concern in this population substantial long-term survival.A total 251 age ≥ 40 years any extent resection or < subtotal resection/biopsy were randomly assigned RT (54 Gy) plus PCV. We observed 111 gross resection. CF was assessed by Mini-Mental State...
Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is national concern. The goal this study was to characterize enrollment trends disparities by age, sex, race/ethnicity lung trials. Methods We analyzed data for 23,006 National Cancer Institute cooperative group trial participants 578,476 from the SEER registry 1990 2012. disparity difference (EDD) ratio (EDR) were calculated on basis proportion each subgroup population US...